Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma GABA in mood disorders.

F Petty1, G L Kramer, D Dunnam

  • 1Psychiatry Service, Department of Veterans Affairs Medical Center, Dallas, TX 75216.

Psychopharmacology Bulletin
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolutions of Delta County Medical Society.

Daniel's Texas medical journal·2023
Same author

The 'difficult-to-treat depression' and the 'response paradigm' models: Implications and relevance to patient management.

The Australian and New Zealand journal of psychiatry·2021
Same author

The identification, assessment and management of difficult-to-treat depression: An international consensus statement.

Journal of affective disorders·2020
Same author

Treatment modalities and outcomes of pleomorphic hyalinizing angiectatic tumor: a systematic review of the literature.

Musculoskeletal surgery·2018
Same author

Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.

Molecular psychiatry·2017
Same author

Point : the top 10 reasons for psychopharmacology supervision.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2014
Same journal

Catatonia Associated with Psychosis: A Retrospective Study of 164 Inpatients.

Psychopharmacology bulletin·2026
Same journal

Escitalopram-Induced Spasmodic Torticollis in an Early Psychosis Service: A Case Report.

Psychopharmacology bulletin·2026
Same journal

Beyond Exposure: Standardizing Buprenorphine Training in Pain Medicine Fellowship.

Psychopharmacology bulletin·2026
Same journal

Association of CBC-Derived Indices of Inflammation with Response to Glecaprevir/Pibrentasvir for PTSD.

Psychopharmacology bulletin·2026
Same journal

When Care Becomes Dangerous: Patient Assaults Against Physicians.

Psychopharmacology bulletin·2026
Same journal

Efficacy and Safety of Centanafadine in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Psychopharmacology bulletin·2026
See all related articles

Low plasma levels of gamma-aminobutyric acid (GABA) were observed in patients with mood disorders compared to healthy individuals. These findings suggest that reduced GABA may serve as a biological marker for mood disorders.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Biochemistry

Background:

  • Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system.
  • Dysregulation of GABAergic systems has been implicated in various psychiatric disorders, including mood disorders.
  • Previous research on plasma GABA levels in mood disorders has yielded inconsistent results.

Purpose of the Study:

  • To investigate plasma levels of GABA in a cohort of patients diagnosed with mood disorders.
  • To compare plasma GABA levels between patients with mood disorders and healthy controls.
  • To explore potential correlations between plasma GABA levels and clinical characteristics of mood disorders.

Main Methods:

  • Plasma GABA concentrations were measured using a validated assay.

Related Experiment Videos

  • A total of 133 patients with various mood disorders and 68 healthy controls participated in the study.
  • Patients were diagnosed according to established criteria, and depression severity was assessed using the Hamilton Rating Scale for Depression.

    • Main Results:

    • Plasma GABA levels were significantly lower in patients with mood disorders compared to healthy controls.
    • No significant differences in plasma GABA levels were found across different diagnostic subgroups (unipolar depression, bipolar depression, mania, secondary depression).
    • Plasma GABA levels did not correlate with family history or depression severity.

    Conclusions:

    • Low plasma GABA levels may represent a potential biological marker for mood disorders.
    • The findings suggest a generalized alteration in GABAergic function in mood disorders, irrespective of specific diagnosis or severity.
    • Further research is warranted to elucidate the role of GABA in the pathophysiology of mood disorders and its potential as a therapeutic target.